Finding difficulties quantifying whether complete doses were delivered from its platform, Quirem Medical engaged National Physical Laboratory (NPL), the UK National Metrology Institute, to calculate a calibration standard for the radionuclide used for an innovative molecular radiotherapy.

The resulting 166Ho calibration standard enabled Quirem Medical to provide more reliable patient dose planning and verification, as the radiopharmaceutical manufacturer could precisely calibrate doses for clinics, and clinics calibrate doses before each treatment. The collaboration also confirmed the suitability of the more user-friendly packaging design, which, according to the company, helped drive commercial adoption.

The project supported effective, better-targeted treatments, and helped clinics maintain compliance with regulations, so advancing the prospect of improved outcomes for cancer patients across Europe.166Ho calibration standard enabled Quirem Medical to provide more reliable patient dose planning and verification.

https://www.euramet.org/casestudies/casestudiesdetails/news/innovation-in-molecular-radiotherapy/